An international venture capital firm dedicated to the cutting edge of advanced therapies, 4BIO Capital, has raised $10.0M to further its investment strategy. The firm focuses solely on the advanced therapies sector, seeking out early-stage companies developing treatments for areas of high unmet medical need.
This includes promising ventures in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome. Its team comprises leading advanced therapy scientists and experienced life science investors, bringing a deep understanding of the space.
